Pasireotide

BreastfeedingPediatric
  • TRADE NAME: Signifor (Novartis)
  • INDICATIONS: Cushing's disease
  • CLASS: Somatostatin analog
  • HALF-LIFE: 12 hours

FDA APPROVAL DATE: 12/14/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antiarrhythmics, Bromocriptine, Cyclosporine, Drugs prolonging the QT interval

PREGNANCY CATEGORY: C

Our database has 57 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
LOCAL
OTHER


Page last updated 11/14/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric